CCL2 and neoplasm: Since the CCL2 KO MSCs showed enhanced anti-tumor effects compared to WT MSCs in mice injected with either TRAMP-C2 or its derived TRAMP-C2/Luc-eGFP cells, we proposed a working model depicting the potential therapeutic benefit of this genetically engineered cell therapy (Figure 5f).